These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 29989040)

  • 1. An Exploratory Study of Daprodustat in Erythropoietin-Hyporesponsive Subjects.
    Cizman B; Sykes AP; Paul G; Zeig S; Cobitz AR
    Kidney Int Rep; 2018 Jul; 3(4):841-850. PubMed ID: 29989040
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Three Times Weekly Dosing of Daprodustat versus Conventional Epoetin for Treatment of Anemia in Hemodialysis Patients: ASCEND-TD: A Phase 3 Randomized, Double-Blind, Noninferiority Trial.
    Coyne DW; Singh AK; Lopes RD; Bailey CK; DiMino TL; Huang C; Connaire J; Rastogi A; Kim SG; Orias M; Shah S; Patel V; Cobitz AR; Wanner C
    Clin J Am Soc Nephrol; 2022 Sep; 17(9):1325-1336. PubMed ID: 35918106
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants with chronic kidney disease.
    Holdstock L; Cizman B; Meadowcroft AM; Biswas N; Johnson BM; Jones D; Kim SG; Zeig S; Lepore JJ; Cobitz AR
    Clin Kidney J; 2019 Feb; 12(1):129-138. PubMed ID: 30746140
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Daprodustat for Treatment of Anemia of Chronic Kidney Disease in Incident Dialysis Patients: A Randomized Clinical Trial.
    Singh AK; Cizman B; Carroll K; McMurray JJV; Perkovic V; Jha V; Johansen KL; Lopes RD; Macdougall IC; Obrador GT; Waikar SS; Wanner C; Wheeler DC; Wiecek A; Stankus N; Strutz F; Blackorby A; Cobitz AR; Meadowcroft AM; Paul G; Ranganathan P; Sedani S; Solomon S
    JAMA Intern Med; 2022 Jun; 182(6):592-602. PubMed ID: 35377393
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of Daprodustat, a Novel Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor on Anemia Management in Japanese Hemodialysis Subjects.
    Akizawa T; Tsubakihara Y; Nangaku M; Endo Y; Nakajima H; Kohno T; Imai Y; Kawase N; Hara K; Lepore J; Cobitz A
    Am J Nephrol; 2017; 45(2):127-135. PubMed ID: 27978511
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of Daprodustat Compared with Darbepoetin Alfa in Japanese Hemodialysis Patients with Anemia: A Randomized, Double-Blind, Phase 3 Trial.
    Akizawa T; Nangaku M; Yonekawa T; Okuda N; Kawamatsu S; Onoue T; Endo Y; Hara K; Cobitz AR
    Clin J Am Soc Nephrol; 2020 Aug; 15(8):1155-1165. PubMed ID: 32723804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Daprodustat Compared with Epoetin Beta Pegol for Anemia in Japanese Patients Not on Dialysis: A 52-Week Randomized Open-Label Phase 3 Trial.
    Nangaku M; Hamano T; Akizawa T; Tsubakihara Y; Nagai R; Okuda N; Kurata K; Nagakubo T; Jones NP; Endo Y; Cobitz AR
    Am J Nephrol; 2021; 52(1):26-35. PubMed ID: 33561857
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of renal function and dialysis modality on daprodustat and predominant metabolite exposure.
    Caltabiano S; Cizman B; Burns O; Mahar KM; Johnson BM; Ramanjineyulu B; Serbest G; Cobitz AR
    Clin Kidney J; 2019 Oct; 12(5):693-701. PubMed ID: 31583094
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants on hemodialysis.
    Meadowcroft AM; Cizman B; Holdstock L; Biswas N; Johnson BM; Jones D; Nossuli AK; Lepore JJ; Aarup M; Cobitz AR
    Clin Kidney J; 2019 Feb; 12(1):139-148. PubMed ID: 30746141
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized, 29-day, dose-ranging, efficacy and safety study of daprodustat, administered three times weekly in patients with anemia on hemodialysis.
    Bailey CK; Caltabiano S; Cobitz AR; Huang C; Mahar KM; Patel VV
    BMC Nephrol; 2019 Oct; 20(1):372. PubMed ID: 31619187
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Daprodustat: A Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor for Anemia of Chronic Kidney Disease.
    Johnson HN; Prasad-Reddy L
    Ann Pharmacother; 2025 Jan; 59(1):71-80. PubMed ID: 38616529
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Daprodustat for the Treatment of Anemia in Patients Undergoing Dialysis.
    Singh AK; Carroll K; Perkovic V; Solomon S; Jha V; Johansen KL; Lopes RD; Macdougall IC; Obrador GT; Waikar SS; Wanner C; Wheeler DC; Więcek A; Blackorby A; Cizman B; Cobitz AR; Davies R; Dole J; Kler L; Meadowcroft AM; Zhu X; McMurray JJV;
    N Engl J Med; 2021 Dec; 385(25):2325-2335. PubMed ID: 34739194
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluating the safety and efficacy of daprodustat for anemia of chronic kidney disease: a meta-analysis of randomized clinical trials.
    Fatima K; Ahmed W; Fatimi AS; Mahmud O; Mahar MU; Ali A; Aamir SR; Nasim MT; Islam MB; Maniya MT; Azim D; Marsia S; Almas T
    Eur J Clin Pharmacol; 2022 Dec; 78(12):1867-1875. PubMed ID: 36195739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Safety of Daprodustat Vs rhEPO for Anemia in Patients With Chronic Kidney Disease: A Meta-Analysis and Trial Sequential Analysis.
    Fu Z; Geng X; Chi K; Song C; Wu D; Liu C; Hong Q
    Front Pharmacol; 2022; 13():746265. PubMed ID: 35359863
    [No Abstract]   [Full Text] [Related]  

  • 15. Regional Variation of Erythropoiesis-Stimulating Agent Hyporesponsiveness in the Global Daprodustat Dialysis Study (ASCEND-D).
    Macdougall IC; Meadowcroft AM; Blackorby A; Cizman B; Cobitz AR; Godoy S; Jha V; Johansen KL; McMahon G; Obrador GT; Wong MG; Singh AK
    Am J Nephrol; 2023; 54(1-2):1-13. PubMed ID: 36739866
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A 24-Week Anemia Correction Study of Daprodustat in Japanese Dialysis Patients.
    Tsubakihara Y; Akizawa T; Nangaku M; Onoue T; Yonekawa T; Matsushita H; Endo Y; Cobitz A
    Ther Apher Dial; 2020 Apr; 24(2):108-114. PubMed ID: 31306555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Novel Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (GSK1278863) for Anemia in CKD: A 28-Day, Phase 2A Randomized Trial.
    Brigandi RA; Johnson B; Oei C; Westerman M; Olbina G; de Zoysa J; Roger SD; Sahay M; Cross N; McMahon L; Guptha V; Smolyarchuk EA; Singh N; Russ SF; Kumar S;
    Am J Kidney Dis; 2016 Jun; 67(6):861-71. PubMed ID: 26827289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Are there advantages of daprodustat over erythropoiesis-stimulating agents (ESAs) in treating anemia associated with chronic kidney disease (CKD)?
    Doggrell SA
    Expert Opin Pharmacother; 2022 May; 23(7):769-773. PubMed ID: 35380500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized, placebo-controlled trial of pentoxifylline on erythropoiesis-stimulating agent hyporesponsiveness in anemic patients with CKD: the Handling Erythropoietin Resistance With Oxpentifylline (HERO) trial.
    Johnson DW; Pascoe EM; Badve SV; Dalziel K; Cass A; Clarke P; Ferrari P; McDonald SP; Morrish AT; Pedagogos E; Perkovic V; Reidlinger D; Scaria A; Walker R; Vergara LA; Hawley CM;
    Am J Kidney Dis; 2015 Jan; 65(1):49-57. PubMed ID: 25115616
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subcutaneous C.E.R.A. for the Maintenance Treatment of Anemia in Pediatric Patients With CKD: A Phase 2, Open-Label, Single-Arm, Multicenter Study.
    Warady BA; Meyer Reigner S; Tirodkar C; Drozdz D
    Am J Kidney Dis; 2023 Jun; 81(6):684-694.e1. PubMed ID: 36587890
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.